CompletedPhase 1/2

The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease

Trinidad and Tobago25 participantsStarted 2019-10-01

Plain-language summary

This study aims to assess the effects of low dose ticagrelor on platelet function testing in patients with stable coronary artery disease.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. between 18 and 74 years of age,
✓. have stable coronary artery disease, already on DAPT with aspirin and clopidogrel for at least 6 months,
✓. not on any physician-prescribed medications or complementary/alternative therapies,

✕. presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding,
✕. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm,
✕. history of clinical and/or hemodynamic instability,
✕. within 1 month of placement of a bare-metal stent,
✕. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed,
✕. planned coronary revascularization,
✕. treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h,
✕. use of an oral anticoagulation agent or international normalized ratio \>1.5,

Clinical effectiveness and safety of low ticagrelor as compared to standard dose clopidogrel based on platelet reaction units (PRU).

Timeframe: 2 weeks

NCT IDNCT04206176

SponsorThe University of The West Indies

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-03-31